Citation: | CHEN Yanqing, GONG Ping, LIU Zhen, ZHANG Yan, YU Yang. Serum amyloid A 3 deficiency improves cognitive impairment and attenuates tau pathology in mouse model of Alzheimer′s disease[J]. Journal of China Pharmaceutical University, 2021, 52(5): 586-595. DOI: 10.11665/j.issn.1000-5048.20210511 |
[1] |
. Science,1982,215(4537):1237-1239.
|
[2] |
Yu Y,Ye RD. Microglial aβ receptors in Alzheimer''s disease[J]. Cell Mol Neurobiol,2015,35(1):71-83.
|
[3] |
Forloni G,Balducci C. Alzheimer''s disease,oligomers,and inflammation[J]. J Alzheimers Dis,2018,62(3):1261-1276.
|
[4] |
Zhang Y,Zhang J,Sheng H,et al. Acute phase reactant serum amyloid A in inflammation and other diseases[J]. Adv Clin Chem,2019,90:25-80.
|
[5] |
Liang JS,Sloane JA,Wells JM,et al. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer''s disease brain[J]. Neurosci Lett,1997,225(2):73-76.
|
[6] |
Miida T,Yamada T,Seino U,et al. Serum amyloid A (SAA)-induced remodeling of CSF-HDL[J]. Biochim Biophys Acta,2006,1761(4):424-433.
|
[7] |
Kindy MS,Yu J,Guo JT,et al. Apolipoprotein serum amyloid A in Alzheimer''s disease[J]. J Alzheimer''s Dis,1999,1(3):155-167.
|
[8] |
Lin A,Liu J,Gong P,et al. Serum amyloid A inhibits astrocyte migration via activating p38 MAPK[J]. J Neuroinflammation,2020,17(1):254.
|
[9] |
Meek RL,Benditt EP. Amyloid A gene family expression in different mouse tissues[J]. J Exp Med,1986,164(6):2006-2017.
|
[10] |
Reigstad CS,Lundén GO,Felin J,et al. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota[J]. PLoS One,2009,4(6):
|
[11] |
Liu J,Wang D,Li SQ,et al. Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A[J]. J Neuroinflammation,2016,13(1):1-15.
|
[12] |
Morris RG,Garrud P,Rawlins JN,et al. Place navigation impaired in rats with hippocampal lesions[J]. Nature,1982,297(5868):681-683.
|
[13] |
DeVos SL,Miller RL,Schoch KM,et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy[J]. Sci Transl Med,2017,9(374):
|
[14] |
Chong FP,Ng KY,Koh RY,et al. Tau proteins and tauopathies in Alzheimer''s disease[J]. Cell Mol Neurobiol,2018,38(5):965-980.
|
[15] |
Chung TF,Sipe JD,McKee A,et al. Serum amyloid A in Alzheimer''s disease brain is predominantly localized to myelin sheaths and axonal membrane[J]. Amyloid,2000,7(2):105-110.
|
[16] |
Jang WY,Lee BR,Jeong J,et al. Overexpression of serum amyloid a 1 induces depressive-like behavior in mice[J]. Brain Res,2017,1654(
|
[17] |
Elder GA,Gama Sosa MA,De Gasperi R,et al. Presenilin transgenic mice as models of Alzheimer''s disease[J]. Brain Struct Funct,2010,214(2/3):127-143.
|
[18] |
Mehla J,Pahuja M,Gupta YK. Streptozotocin-induced sporadic Alzheimer''s disease:selection of appropriate dose[J]. J Alzheimers Dis,2013,33(1):17-21.
|
[19] |
Voronkov DN,Stavrovskaya AV,Stelmashook EV,et al. Neurodegenerative changes in rat brain in streptozotocin model of Alzheimer''s disease[J]. Bull Exp Biol Med,2019,166(6):793-796.
|
[20] |
Kamat PK,Kalani A,Rai S,et al. Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance:a therapeutic intervention for treatment of sporadic Alzheimer''s disease (sAD)-like pathology[J]. Mol Neurobiol,2016,53(7):4548-4562.
|
[21] |
Li SQ,Yu Y,Han JZ,et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer''s disease[J]. J Neuroinflammation,2015,12:177.
|
[22] |
Gonzalez-Pena D,Nixon SE,O''Connor JC,et al. Microglia transcriptome changes in a model of depressive behavior after immune challenge[J]. PLoS One,2016,11(3):
|
[23] |
Selles MC,Oliveira MM,Ferreira ST. Brain inflammation connects cognitive and non-cognitive symptoms in Alzheimer''s disease[J]. J Alzheimers Dis,2018,64(s1):S313-S327.
|
[24] |
Bussian TJ,Aziz A,Meyer CF,et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline[J]. Nature,2018,562(7728):578-582.
|
[1] | CHEN Feihong, ZHAO Deming, GOU Shaohua. Research progress on the antitumor effects of platinum-based chemo-immunotherapies[J]. Journal of China Pharmaceutical University, 2024, 55(1): 26-35. DOI: 10.11665/j.issn.1000-5048.2023120201 |
[2] | XU Yungen. Advances in drug development based on immunoregulation[J]. Journal of China Pharmaceutical University, 2024, 55(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2024022601 |
[3] | YU Dongmei, GUO Wei, LEI Wen, GE Yaoyao, CHEN Yucong, GAO Xiangdong, YAO Wenbing. Advances of lncRNA in immune cells and autoimmune diseases[J]. Journal of China Pharmaceutical University, 2017, 48(3): 371-376. DOI: 10.11665/j.issn.1000-5048.20170319 |
[4] | LIANG Xiao-qing, SHI Chen-yang, WANG Ke, HE Xin, LIU Si-guo, HUANG Xiao-feng, LIU Yu. Anti-angiogenesis and anti-tumor activity of the fully human anti-VEGF165 monoclonal antibody obtained from the five-feature transgenic mice[J]. Journal of China Pharmaceutical University, 2012, 43(6): 560-566. |
[5] | Tumor microenvironment:A novel target for antitumor activity of polysaccharides[J]. Journal of China Pharmaceutical University, 2010, 41(1): 1-10. |
[8] | Effects of Mixed Nucleotide on Acute Hepatic Injury and Immunoregulation in Mice[J]. Journal of China Pharmaceutical University, 2001, (6): 44-47. |
[9] | Immunomodulating Activity of Yang Zheng He Ji[J]. Journal of China Pharmaceutical University, 1995, (1): 37-40. |
[10] | The Immunoregulative Effect of the Synthetic Artifact of Royel Jelly Acid[J]. Journal of China Pharmaceutical University, 1991, (2): 117-118. |